Summary & Overview
HCPCS Q9978: Netupitant 300 mg and Palonosetron 0.5 mg
HCPCS Level II code Q9978 designates the combined antiemetic formulation of netupitant 300 mg and palonosetron 0.5 mg. This fixed-dose combination is used to prevent acute and delayed chemotherapy-induced nausea and vomiting and is relevant for outpatient oncology care nationwide. As an HCPCS Level II code, Q9978 identifies the specific medication product for billing and reimbursement in medical benefit settings.
Key national payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the combination therapy, typical sites of service where the product is used, and which major payers are addressed. The publication outlines benchmarks and policy considerations relevant to coverage and coding for oral antiemetic agents, summarizes common billing scenarios, and highlights where readers can expect variability in payer approaches.
This summary delivers practical coding and policy context for providers, billing staff, and administrators working in oncology services. It clarifies what Q9978 represents, why accurate product-level coding matters for claims processing and benefit determination, and what topics—such as coverage policies, reimbursement benchmarks, and clinical use cases—are covered in the full publication.
Billing Code Overview
HCPCS Level II code Q9978 describes netupitant 300 mg and palonosetron 0.5 mg, a fixed-combination antiemetic medication used to prevent chemotherapy-induced nausea and vomiting. The service represented by this code is administration or provision of the combined oral antiemetic therapy.
-
Service type: Oral antiemetic combination therapy
-
Typical site of service: Outpatient oncology clinics, infusion centers, and other ambulatory settings where patients receive chemotherapy or supportive cancer therapies
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult oncology patient scheduled to receive moderately or highly emetogenic chemotherapy for solid tumor treatment (for example, cisplatin-based or anthracycline/cyclophosphamide regimens). Prior to chemotherapy administration in the outpatient infusion center, an oncology nurse or pharmacist prepares an oral antiemetic regimen that includes the fixed-dose combination of netupitant 300 mg and palonosetron 0.5 mg (Q9978) to prevent acute and delayed chemotherapy-induced nausea and vomiting (CINV). The clinical workflow includes verification of the chemotherapy order, assessment of prior CINV control and current symptoms, reconciliation of current medications for interactions (notably CYP3A4 inducers/inhibitors), informed consent for supportive medications, administration of antiemetics (oral agent given or dispensed with documented time relative to chemotherapy start), and monitoring for adverse effects such as headache, constipation, or QT prolongation. Electronic documentation captures the administered Q9978 product, lot number, timing relative to chemotherapy, and the associated ICD-10 diagnosis code(s) for the malignancy and/or nausea/vomiting used for billing and utilization review. Typical sites of service are outpatient hospital infusion centers, freestanding oncology infusion clinics, and physician office infusion suites. Typical patient scenario: a 58-year-old female with newly diagnosed ovarian cancer receiving carboplatin/paclitaxel in an outpatient infusion center; antiemetic prophylaxis includes Q9978 given 60 minutes before chemotherapy, with oral dexamethasone and an as-needed prescription for breakthrough nausea.
Coding Specifications
| Modifier | Description |
|---|